Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Cussenot, O.; Azzouzi, A.R.; Nicolaiew, N.; Mangin, P.; Cormier, L.; Fournier, G.; Valeri, A.; Cancel-Tassin, G.
    Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors (2007), Eur. Urol., 52, 1082-1087.
    View publication on PubMed

Protein Variants

EC Number Protein Variants Comment Organism
1.3.1.22 V89L the mutant of low 5-alpha-reductase type 2 activity is associated with an increased risk of aggressive prostate cancer Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
1.3.1.22 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
1.3.1.22 prostate adenocarcinoma cell
-
 Homo sapiens
-
1.3.1.22 prostate gland
-
 Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
1.3.1.22 testosterone + NADPH + H+
-
 Homo sapiens 5alpha-dihydrotestosterone + NADP+ + H+
-
 ?

Synonyms

EC Number Synonyms Comment Organism
1.3.1.22 5-alpha-reductase type 2
-
 Homo sapiens
1.3.1.22 5A2
-
 Homo sapiens

Cofactor

EC Number Cofactor Comment Organism Structure
1.3.1.22 NADPH
-
 Homo sapiens